Karyopharm Therapeutics Inc Financials
This page shows Karyopharm Therapeutics Inc (KPTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Karyopharm Therapeutics Inc has an operating margin of -62.1%, meaning the company retains $-62 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -82.2% the prior year.
Karyopharm Therapeutics Inc's revenue grew a modest 0.6% year-over-year to $146.1M. This slow but positive growth earns a score of 34/100.
Karyopharm Therapeutics Inc's current ratio of 1.12 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 17/100, which could limit financial flexibility.
While Karyopharm Therapeutics Inc generated -$75.4M in operating cash flow, capex of $0 consumed most of it, leaving -$75.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Karyopharm Therapeutics Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Karyopharm Therapeutics Inc generates $0.38 in operating cash flow (-$75.4M OCF vs -$196.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Karyopharm Therapeutics Inc earns $-2.0 in operating income for every $1 of interest expense (-$90.7M vs $45.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Karyopharm Therapeutics Inc generated $146.1M in revenue in fiscal year 2025. This represents an increase of 0.6% from the prior year.
Karyopharm Therapeutics Inc's EBITDA was -$90.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.1% from the prior year.
Karyopharm Therapeutics Inc reported -$196.0M in net income in fiscal year 2025. This represents a decrease of 156.5% from the prior year.
Karyopharm Therapeutics Inc earned $-17.93 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 28.1% from the prior year.
Cash & Balance Sheet
Karyopharm Therapeutics Inc generated -$75.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 40.9% from the prior year.
Karyopharm Therapeutics Inc held $60.5M in cash against $0 in long-term debt as of fiscal year 2025.
Karyopharm Therapeutics Inc had 18M shares outstanding in fiscal year 2025. This represents a decrease of 85.5% from the prior year.
Margins & Returns
Karyopharm Therapeutics Inc's operating margin was -62.1% in fiscal year 2025, reflecting core business profitability. This is up 20.1 percentage points from the prior year.
Karyopharm Therapeutics Inc's net profit margin was -134.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 81.6 percentage points from the prior year.
Capital Allocation
Karyopharm Therapeutics Inc invested $125.6M in research and development in fiscal year 2025. This represents a decrease of 12.3% from the prior year.
Karyopharm Therapeutics Inc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
KPTI Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.1M-22.6% | $44.0M+16.1% | $37.9M+26.4% | $30.0M-1.7% | $30.5M-21.2% | $38.8M-9.4% | $42.8M+29.2% | $33.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $27.7M-9.4% | $30.5M-6.8% | $32.8M-5.3% | $34.6M+4.0% | $33.3M-7.8% | $36.1M-5.8% | $38.4M+8.3% | $35.4M |
| SG&A Expenses | $22.8M-14.4% | $26.6M-6.6% | $28.5M+4.1% | $27.4M+0.6% | $27.2M-1.6% | $27.6M-11.1% | $31.1M+5.1% | $29.5M |
| Operating Income | -$17.8M-17.2% | -$15.2M+37.6% | -$24.4M+26.7% | -$33.3M-6.3% | -$31.3M-19.0% | -$26.3M+6.5% | -$28.1M+16.7% | -$33.8M |
| Interest Expense | $12.6M+14.6% | $11.0M-2.0% | $11.2M+2.1% | $11.0M-1.9% | $11.2M-1.6% | $11.4M+27.2% | $8.9M+52.1% | $5.9M |
| Income Tax | -$67K-297.1% | $34K-15.0% | $40K+11.1% | $36K+133.0% | -$109K-489.3% | $28K-58.2% | $67K-5.6% | $71K |
| Net Income | -$102.2M-208.5% | -$33.1M+11.1% | -$37.3M-58.8% | -$23.5M+23.8% | -$30.8M+4.0% | -$32.1M-234.8% | $23.8M+163.7% | -$37.4M |
| EPS (Diluted) | N/A | $-3.82 | $-4.32-56.0% | $-2.77 | N/A | $-3.85-29.6% | $-2.97+38.8% | $-4.85 |
KPTI Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $108.4M+12.7% | $96.2M-8.2% | $104.9M-17.9% | $127.7M-22.3% | $164.4M-13.2% | $189.5M-11.5% | $214.0M+4.7% | $204.5M |
| Current Assets | $103.1M+14.9% | $89.7M-8.3% | $97.9M-18.6% | $120.2M-23.2% | $156.5M-15.3% | $184.8M-11.4% | $208.5M+5.1% | $198.4M |
| Cash & Equivalents | $60.5M+60.7% | $37.7M-2.7% | $38.7M-0.1% | $38.8M-37.9% | $62.5M-14.2% | $72.8M-14.1% | $84.8M+176.8% | $30.6M |
| Inventory | $4.0M+1.8% | $4.0M-20.6% | $5.0M+4.7% | $4.8M+0.6% | $4.7M+1.4% | $4.7M+34.4% | $3.5M+25.5% | $2.8M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $401.3M+9.8% | $365.5M+6.3% | $343.8M+3.1% | $333.6M-4.8% | $350.4M+0.4% | $349.1M+0.9% | $346.1M-7.3% | $373.4M |
| Current Liabilities | $92.1M+5.6% | $87.2M-12.2% | $99.2M+9.8% | $90.4M-2.1% | $92.3M+50.0% | $61.5M+6.7% | $57.6M-11.8% | $65.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$292.9M-8.8% | -$269.3M-12.7% | -$238.9M-16.0% | -$205.9M-10.7% | -$186.0M-16.5% | -$159.6M-20.8% | -$132.1M+21.8% | -$169.0M |
| Retained Earnings | -$1.8B-6.2% | -$1.7B-2.0% | -$1.6B-2.3% | -$1.6B-1.5% | -$1.6B-2.0% | -$1.5B-2.1% | -$1.5B+1.6% | -$1.5B |
KPTI Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.8M-101.8% | -$5.9M+68.7% | -$18.7M+52.0% | -$39.0M-51.0% | -$25.8M-32.7% | -$19.5M+49.5% | -$38.5M+12.0% | -$43.7M |
| Capital Expenditures | $0 | $0 | $0 | $0+100.0% | -$53K | $0 | $0-100.0% | $195K |
| Free Cash Flow | -$11.8M-101.8% | -$5.9M+68.7% | -$18.7M+52.0% | -$39.0M-50.7% | -$25.9M-33.0% | -$19.5M+49.5% | -$38.5M+12.3% | -$43.9M |
| Investing Cash Flow | $5.0M+4.1% | $4.8M-73.7% | $18.3M+19.6% | $15.3M+3.3% | $14.8M+98.0% | $7.5M-85.4% | $51.3M+133.6% | $21.9M |
| Financing Cash Flow | $29.7M | $0 | N/A | N/A | $680K | $0 | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
KPTI Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -52.4%-17.8pp | -34.6%+29.7pp | -64.3%+46.5pp | -110.8%-8.4pp | -102.4%-34.7pp | -67.8%-2.0pp | -65.7%+36.2pp | -101.9% |
| Net Margin | -299.9%-224.7pp | -75.2%+23.0pp | -98.2%-20.1pp | -78.2%+22.6pp | -100.8%-18.1pp | -82.7%-138.3pp | 55.6%+168.4pp | -112.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -94.3%-59.8pp | -34.4%+1.1pp | -35.5%-17.2pp | -18.4%+0.4pp | -18.7%-1.8pp | -16.9%-28.0pp | 11.1%+29.4pp | -18.3% |
| Current Ratio | 1.12+0.1 | 1.03+0.0 | 0.99-0.3 | 1.33-0.4 | 1.70-1.3 | 3.00-0.6 | 3.62+0.6 | 3.04 |
| Debt-to-Equity | -1.37-0.0 | -1.36+0.1 | -1.44+0.2 | -1.62+0.3 | -1.88+0.3 | -2.19+0.4 | -2.62-0.4 | -2.21 |
| FCF Margin | -34.7%-21.4pp | -13.3%+36.0pp | -49.3%+80.6pp | -129.9%-45.2pp | -84.7%-34.5pp | -50.2%+39.8pp | -90.0%+42.6pp | -132.6% |
Note: Shareholder equity is negative (-$292.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Karyopharm Therapeutics Inc's annual revenue?
Karyopharm Therapeutics Inc (KPTI) reported $146.1M in total revenue for fiscal year 2025. This represents a 0.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Karyopharm Therapeutics Inc's revenue growing?
Karyopharm Therapeutics Inc (KPTI) revenue grew by 0.6% year-over-year, from $145.2M to $146.1M in fiscal year 2025.
Is Karyopharm Therapeutics Inc profitable?
No, Karyopharm Therapeutics Inc (KPTI) reported a net income of -$196.0M in fiscal year 2025, with a net profit margin of -134.2%.
What is Karyopharm Therapeutics Inc's EBITDA?
Karyopharm Therapeutics Inc (KPTI) had EBITDA of -$90.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Karyopharm Therapeutics Inc's operating margin?
Karyopharm Therapeutics Inc (KPTI) had an operating margin of -62.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Karyopharm Therapeutics Inc's net profit margin?
Karyopharm Therapeutics Inc (KPTI) had a net profit margin of -134.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Karyopharm Therapeutics Inc's free cash flow?
Karyopharm Therapeutics Inc (KPTI) generated -$75.4M in free cash flow during fiscal year 2025. This represents a 40.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Karyopharm Therapeutics Inc's operating cash flow?
Karyopharm Therapeutics Inc (KPTI) generated -$75.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Karyopharm Therapeutics Inc's total assets?
Karyopharm Therapeutics Inc (KPTI) had $108.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Karyopharm Therapeutics Inc's capital expenditures?
Karyopharm Therapeutics Inc (KPTI) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Karyopharm Therapeutics Inc spend on research and development?
Karyopharm Therapeutics Inc (KPTI) invested $125.6M in research and development during fiscal year 2025.
What is Karyopharm Therapeutics Inc's current ratio?
Karyopharm Therapeutics Inc (KPTI) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.
What is Karyopharm Therapeutics Inc's debt-to-equity ratio?
Karyopharm Therapeutics Inc (KPTI) had a debt-to-equity ratio of -1.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Karyopharm Therapeutics Inc's return on assets (ROA)?
Karyopharm Therapeutics Inc (KPTI) had a return on assets of -180.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Karyopharm Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Karyopharm Therapeutics Inc (KPTI) had $60.5M in cash against an annual operating cash burn of $75.4M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Karyopharm Therapeutics Inc's debt-to-equity ratio negative or unusual?
Karyopharm Therapeutics Inc (KPTI) has negative shareholder equity of -$292.9M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Karyopharm Therapeutics Inc's Piotroski F-Score?
Karyopharm Therapeutics Inc (KPTI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Karyopharm Therapeutics Inc's earnings high quality?
Karyopharm Therapeutics Inc (KPTI) has an earnings quality ratio of 0.38x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Karyopharm Therapeutics Inc cover its interest payments?
Karyopharm Therapeutics Inc (KPTI) has an interest coverage ratio of -2.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Karyopharm Therapeutics Inc?
Karyopharm Therapeutics Inc (KPTI) scores 13 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.